Verastem VSTM
NASDAQ VSTM
$8.20 +0.22 (+2.82%)
As of: Sep 4, 2026 · 3:59 PM EDT

Verastem (VSTM) Cash from Financing Activities (2011 - 2026)

Verastem (VSTM) posted quarterly Cash from Financing Activities of $28.7 million for Q1 2026, down 57.45% year-over-year from $67.4 million in Q1 2025, and down 70.9% quarter-over-quarter from $98.6 million in Q4 2025.

Analysis

Verastem (VSTM) Cash from Financing Activities (2011 - 2026) Analysis & Trends

Verastem's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $28.7 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities fell 57.45% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $224.6 million (up 85.04% YoY), while the FY2025 annual figure was $263.3 million, up 380.64% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $28.7 million, down from $98.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $98.6 million in Q4 2025, with the low at -$891000.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $25.5 million (2022), against an average of $33.3 million.
  • The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 103.48% in 2023, then jumped 19708.89% in 2025.
  • Verastem's Cash from Financing Activities stood at $25.6 million in 2022, then tumbled by 101.74% to -$446000.0 in 2023, then jumped by 266.37% to $742000.0 in 2024, then surged by 13186.12% to $98.6 million in 2025, then sank by 70.9% to $28.7 million in 2026.
  • Business Quant data shows VSTM's Cash from Financing Activities at $28.7 million in Q1 2026, $98.6 million in Q4 2025, and $17.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Verastem 814.94 Mn 678.59 Mn 36.32 Mn -1.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.54 Mn
Mar 31, 2026 28.69 Mn
Dec 31, 2025 98.58 Mn
Sep 30, 2025 17.88 Mn
Jun 30, 2025 79.42 Mn
Mar 31, 2025 67.43 Mn
Dec 31, 2024 742,000.00
Sep 30, 2024 53.60 Mn
Jun 30, 2024 -405,000.00
Mar 31, 2024 846,000.00
Dec 31, 2023 -446,000.00
Sep 30, 2023 -891,000.00
Jun 30, 2023 91.48 Mn
Mar 31, 2023 44.05 Mn
Sep 30, 2022 25.62 Mn
Jun 30, 2022 708,000.00
Mar 31, 2022 25.45 Mn
Dec 31, 2021 6.81 Mn
Sep 30, 2021 169,000.00
Jun 30, 2021 489,000.00